ALBUQUERQUE, N.M., January 22, 2008/PRNewswire-FirstCall/-- Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology announced today it has retained the services of Terry McDermott of McDermott Consulting to facilitate communication and lobbying efforts during the current 2008 New Mexico Legislative session.
McDermott has more than 27 years experience in communication including television and print media. He spent most of the last ten years as communications manager with Intel Corporation and was responsible for internal and external communication. McDermott also served as Intel government relations manager where he lobbied the N.M. State Legislature, the U.S Congressional Delegation as well as municipal and county governments.
“Terry’s experience, notoriety and extensive relationships within the community and government circles are critical to our efforts” said John Cousins, President of Biomoda. “We look to tap into not only his lobbying expertise but also his public relations and a media relations talent as the company continues to grow.”
After retiring from professional baseball McDermott enjoyed an award winning career as a television sports journalist in Albuquerque where he earned eight, New Mexico “Sportscaster of the Year” honors from the National Sportscasters and Sportswriters’ Association.
As Intel spokesperson and communications manager in New Mexico McDermott developed media strategies around the Intel $16 billion Industrial Revenue Bond with Sandoval County, site expansions, workforce reductions, and environmental activist opposition. McDermott developed and executed legislative strategies around tax incentives, environmental issues, business development and healthcare.
“I look forward to spreading the word about Biomoda among legislators, military veterans and the general public” said McDermott. “The development and testing of this cutting edge technology will be a benefit to us all.”
Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
Contact: John Cousins (505) 821-0875
SOURCE Biomoda, Inc.